Explore press releases
Filter
Topics
Period
Filter by
recent search
Showing: 1 – 05 of 18 Press Releases
–
26 September 2019
26 September 2019
 for the Treatment of Upper LimbSpasticity in Children, Excluding Cerebral Palsy&media=https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/sites/2/2023/05/02112724/PR-final.jpg "Share on LinkedIn")
LinkedIn
Twitter
Facebook
Ipsen Announces FDA Approval of Dysport®(abobotulinumtoxinA) for the Treatment of Upper LimbSpasticity in Children, Excluding Cerebral Palsy
– Dysport is the first and only FDA-approved botulinum toxin for treatment of both pediatricupper and lower limb spasticity1 –– Pivotal Phase 3 study demonstrated Dysport improved spasticity symptoms in children agedtwo to 17 experiencing upper limb spasticity, as measured…
–
24 June 2019
24 June 2019
&media=https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/sites/2/2023/05/02112724/PR-final.jpg "Share on LinkedIn")
LinkedIn
Ipsen Announces U.S. FDA Approval for Newly DesignedPre-Filled Syringe for Somatuline® Depot (lanreotide)
– New Syringe Designed to Help Enhance Injection Experience –Cambridge, Mass., June 24, 2019 – Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR:IPSEY), announced today that the United States Food and Drug Administration (FDA) has approved a newpre-filled syringe…
–
19 June 2019
19 June 2019
LinkedIn
Ipsen Celebrates Opening of New Cambridge Headquarters with Day of Service
– Ipsen officially opens North American headquarters at One Main Street and recently renovatedR&D and Global External Innovation and Partnering facilities at 650 East Kendall Street –– More than 115 employees join together to support nine local non-profit organizations –Cambridge,…